2021 Fiscal Year Final Research Report
Novel method for treating myocardium infarction by using cardiac tissue ring matured by spontaneous traveling wave
Project/Area Number |
19K12801
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 90120:Biomaterials-related
|
Research Institution | Osaka University |
Principal Investigator |
LI JUNJUN 大阪大学, 医学系研究科, 特任助教(非常勤) (10723786)
|
Co-Investigator(Kenkyū-buntansha) |
南 一成 大阪大学, 医学系研究科, 特任准教授(常勤) (40362537)
|
Project Period (FY) |
2019-04-01 – 2022-03-31
|
Keywords | pluripotent stem cells / tissue engineering / cardiomyocytes / regenerative medicine / cell maturation |
Outline of Final Research Achievements |
Cardiomyocytes derived from human iPSCs are expected to repair the infarcted heart, however, their maturation level could affect the therapeutic effect. Supported by the present project, we prepared the matured self-organized tissue rings and evaluate their therapeutic effect on the rat heart with myocardium infarction. The achivements are as following: 1.The matured tissue sheet paced by the traveling wave have been prepared. The cardiac-specific markers have been verified. 2.The mature tissue group demonstrated an improved therapeutic effect on the rat heart with myocardial infarction compared with the control group. In addition, we find the improved survival rate and improved therapeutic effect of matured tissue could be related to the higher expression of myoglobin, cytochrome C, and other maturation related markers. 3. We published 3 papers and applied for 1 patent, we gave an oral presentation at 2021 American Heart Association conference.
|
Free Research Field |
tissue engineering
|
Academic Significance and Societal Importance of the Research Achievements |
This technology could be used to produce matured iPSC-derived cardiac tissue for treating infarcted hearts. We expect that this new technology could be of great usefulness and importance for both researchers and clinical users working on developing regenerative therapy for the human heart.
|